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The folding, misfolding, and degradation of membrane proteins is controlled by multiple 
processes within the cell. In this issue of Cell, Wang et al. (2006) present an interactome for 
CFTR, the chloride channel that is misfolded and prematurely degraded in cystic fibrosis. 
Among the proteins interacting with CFTR is a new member of the Hsp90 chaperone system, 
Aha1, that plays a central role in CFTR folding.Protein folding in cells is facilitated by 
several elegant chaperone machines 
that improve folding efficiency and 
minimize the occurrence of mis-
folded proteins in a crowded macro-
molecular environment. The central 
components of these machines are 
finely tuned by regulators, or cochap-
erones, that balance the kinetic and 
thermodynamic constraints of client 
proteins and thus create an environ-
ment (termed folding solvent) to opti-
mize correct folding (Kelly and Balch, 
2006). Many components of this sys-
tem also recognize misfolded pro-
teins and facilitate their degradation 
through the ubiquitin proteasome sys-
tem. These competing pathways for 
protein maturation and degradation 
intersect in the endoplasmic reticulum 
(ER), where nearly a third of the cel-
lular proteome is synthesized, folded, 
and packaged for transport (Younger 
et al., 2006). In this issue, Wang et al., 
(2006) provide new insight into the complexity of protein networks that 
populate the secretory pathway. They 
identify new factors that govern the 
fate of the cystic fibrosis transmem-
brane conductance regulator (CFTR), 
an apical membrane ATP-regulated 
chloride channel whose misfolding is 
implicated in cystic fibrosis.
Cystic fibrosis is an inherited dis-
ease of epithelial tissues caused 
primarily by point mutations that 
disrupt CFTR folding and delivery to 
the plasma membrane (Cheng et al., 
1990). CFTR folding takes place in the 
ER and requires the precise organiza-
tion of two transmembrane domains 
and three cytosolic domains prior to 
export (Xiong et al., 1997). In most 
cells, this process is both complex 
and inefficient (ure 1). Degradation 
approaches 100% for the major dis-
ease-related mutant, ∆F508, which is 
found in more than 90% of individu-
als with cystic fibrosis. Once folded, 
however, ∆F508 CFTR can traffic to Cell 127, Novethe plasma membrane and partially 
restore chloride transport. Thus, 
interventions that could restore ∆F508 
folding are of major clinical interest.
Wang et al., (2006) now address 
this problem using multidimensional 
protein identification technology 
(MudPIT) to identify nearly 200 pro-
teins (the “interactome”) from four 
different cell types that coimmuno-
precipitate with either wild-type or 
∆F508 CFTR. Some of these interac-
tions were either known or predicted 
based on prior studies of CFTR sta-
bility, trafficking, and endocytosis. 
However, the largest group—more 
than two-thirds of the proteins identi-
fied—have no known function related 
to CFTR. Even though some known 
interactions were not identified in 
this screen, which indicates that the 
total interactome is not yet complete, 
these data provide a valuable start-
ing point for further study. Notably, 
the presence of several elaborate mber 17, 2006 ©2006 Elsevier Inc. 673
and interconnected sub-
networks suggests that 
CFTR directly or indirectly 
impacts cellular processes 
that extend far beyond its 
role as an ion channel.
One of the most interest-
ing findings to emerge from 
this analysis is the extent 
to which CFTR associ-
ates with the cytosolic and 
lumenal folding machin-
ery. Multiple chaperones, 
including calnexin, Hsp40, 
Hsp70, and Hsp90, were 
known to bind wild-type 
and mutant forms of CFTR. 
Although Hsp70 decreased 
aggregation of purified 
CFTR cytosolic domains 
in vitro, in cells it appeared 
to primarily inhibit sur-
face expression of ∆F508 
CFTR. By contrast, Hsp90 
stimulated the maturation 
of ∆F508 CFTR in a manner 
analogous to its role in the 
activation of kinases and 
steroid hormone receptors 
(Loo et al., 1998; Wegele, 
et al., 2004). Because the 
Hsp70 and Hsp90 systems 
are functionally linked by 
regulatory cochaperones 
that promote the exchange 
of the initial interaction with 
Hsp40/70 for cargo-spe-
cific Hsp90 folding com-
plexes, early proposals 
suggested that the fate of 
CFTR in the ER might be 
controlled through a similar 
mechanism. This specula-
tion was gradually substan-
tiated by many groups who 
demonstrated that Hsp70 
could promote either CFTR 
maturation or degradation, 
depending on the particu-
lar complement of cochap-
erones present (reviewed 
in Amaral, 2004).
Wang and colleagues now 
identify 31 chaperones and 
cochaperones for CFTR, 
many of which preferentially 
bind to ∆F508. These chap-
erones and cochaperones 674 Cell 127, November 17, 2figure 1. chaperones and cfTR folding
A model depicts the chaperone-assisted pathway for the folding of 
CFTR (cystic fibrosis transmembrane conductance regulator). During 
CFTR synthesis, transmembrane domains are integrated into the en-
doplasmic reticulum (ER) membrane by the Sec61 translocon, and 
cytosolic/lumenal chaperones initiate binding to the nascent unfolded 
polypeptide. Deletion of Phe508 in the first nucleotide-binding do-
main (NBD1) is a common cause of cystic fibrosis. ATP-dependent 
Hsp40/70 cycling results in the recruitment of HOP, p50/Cdc37, and 
p23, which stimulate loading of client-specific Hsp90 complexes that 
facilitate maturation of the CFTR fold. Hsp90 ATPase activity and cy-
cling is stimulated by Aha1, and late complexes are released to allow 
CFTR packaging into ER export vesicles. The stoichiometry, tempo-
ral recruitment, and displacement of chaperone complexes are not 
known. However, it is likely that the complement of cytosolic/lume-
nal chaperones is highly dynamic and evolves toward more mature 
Hsp90 complexes as folding proceeds. Failure of CFTR to achieve a 
stable fold (during Hsp70/90 cycling) tips the balance of this cellular 
program to favor the recruitment of cofactors that promote degrada-
tion. This results in CFTR polyubiquitination, membrane extraction, 
and degradation by VCP, proteasomes, and other membrane-bound 
and cytosolic components.006 ©2006 Elsevier Inc.were found to be associated 
with wild-type or ∆F508 
CFTR stably expressed in 
baby hamster kidney (BHK) 
cells. The authors propose 
that these proteins com-
prise the minimal cellular 
folding environment, or 
“chaperome,” that collec-
tively determines whether 
∆F508 CFTR achieves ener-
getically favorable folding or 
is targeted for degradation. 
Detailed analysis of three 
cochaperones, p23, FKBP8, 
and Aha1, firmly places 
Hsp90 at this decision point 
(Figure 1). The cochaperone 
p23 inhibits Hsp90 ATPase 
activity, stimulates formation 
of the Hsp90 folding com-
plex, and stabilizes Hsp90 
binding to client proteins 
(Wegele et al., 2004). Con-
sistent with this, Wang et al. 
show that reduction of p23 
levels in human embryonic 
kidney (HEK) cells increases 
degradation of ∆F508 CFTR, 
whereas overexpression 
prevents degradation but 
does not enhance traffick-
ing. The simplest explana-
tion is that reducing levels 
of p23 inhibits transfer to 
Hsp90 and thus shifts the 
balance of immature ∆F508 
CFTR binding to favor 
Hsp70 complexes that sub-
sequently recruit cofactors 
and promote degradation. 
Persistent Hsp90 binding in 
the presence of excess p23 
might additionally sequester 
CFTR and prevent its pack-
aging into COPII vesicles in 
the ER for export. Further 
analysis of how manipulat-
ing p23 expression affects 
the binding of chaperones 
to CFTR will be needed 
to determine whether this 
model is correct.
Of the purified cochap-
erones studied in detail, 
Aha1 mediated the most 
remarkable effects. Aha1 
is a potent stimulator of 
Hsp90 ATPase activity that acts as a 
late cofactor of the Hsp90 complex 
(Panaretou et al., 2002; Wegele et al., 
2004). Wang et al., (2006) show that 
overexpression of Aha1 markedly 
destabilized ∆F508 CFTR, whereas its 
downregulation significantly improved 
stability, trafficking, and delivery of 
functional ∆F508 CFTR to the plasma 
membrane. Reduction of Aha1 protein 
levels decreased ∆F508 CFTR binding 
to Hsp90 but did not appear to induce 
cellular stress or alter the levels of 
other chaperones. These findings are 
surprising for several reasons. First, 
Aha1 enhances ∆F508 CFTR degra-
dation, whereas it has been shown 
to promote activation of other Hsp90 
clients (Wegele et al., 2004). Second, 
the downregulation of p23 destabi-
lized ∆F508 CFTR despite predictions 
that p23 downregulation should also 
decrease CFTR binding to Hsp90. 
Although several scenarios could be 
envisioned, these data suggest that 
Aha1 blocks CFTR-Hsp90 interac-
tions in a manner very different from 
p23 and that the outcome depends 
on where in the Hsp90 pathway these 
cofactors act. If p23 facilitates client 
transfer from the Hsp70 to the Hsp90 
system as has been proposed, then 
less CFTR would be transferred to The tumor-suppressor protein p53 is 
a key regulator of cell-cycle control, 
apoptosis, and genomic stability. 
Under normal growth conditions, the 
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scriptional activation rather t
how p53 can modulate diversHsp90 when p23 levels were reduced. 
In contrast, a reduction in Aha1 might 
induce late release of CFTR from the 
mature Hsp90 complex, perhaps after 
a transport-permissive conformation 
is achieved. One intriguing possibility 
is that decreasing the levels of Aha1 
allows ∆F508 CFTR increased time 
to bypass a proposed kinetic block 
in folding (Qu et al., 1997). A detailed 
understanding of the temporal recruit-
ment of these and other cochaperones 
will be needed in order to determine 
how the balance of Aha1 and Hsp90 
cycling perturbs the folding environ-
ment to favor ∆F508 maturation.
What is clear from these studies is 
that maturation of at least some pro-
teins that are prone to misfolding can 
be enhanced by manipulation of both 
the Hsp70 and Hsp90 chaperone sys-
tems. For the moment, Wang et al., 
(2006) have focused attention on an 
important decision point that likely 
involves the handoff of client proteins 
from Hsp40/70 to the Hsp90 fold-
ing complex. The next challenge will 
be to determine which of the many 
newly implicated components of this 
network can be targeted to promote 
maturation of specific cargos with 
little cost in terms of toxicity to the 
cell. Such a strategy might be used Cell 127, Nov
stability of the p53 protein is tightly 
regulated. At least five ubiquitin 
ligases (E6-AP, Hdm2, Cop1, Pirh2, 
and ARF-BP1) have been shown to 
n for p53 Ubiq
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 cell is normally limited by ubiq
t al. (2006) reveal that p53 ubiq
han protein stability. These res
e cellular processes such as grin therapies for diseases associated 
with protein misfolding, including 
cystic fibrosis.
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